Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | CTSL | P07711 | 4/20 | 0.63 |
| ▸ | CTSB | P07858 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 2/20 | 0.63 |
| ▸ | CTSK | P43235 | 2/20 | 0.63 |
| ▸ | TACR1 | P25103 | 2/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434107 | 1.00 | ALDH1A1 (0.65) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| Hypochlorous Acid SCHEMBL7368156 | 0.96 | TACR1 (0.65) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL8583913 | 0.95 | CTSL (0.65) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| Aniline SCHEMBL8510048 | 0.94 | ALDH1A1 (0.59) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| Glycine SCHEMBL7320734 | 0.94 | ITGB3 (0.61) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL479010 | 0.93 | TACR1 (0.68) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL219151 | 0.93 | TACR1 (0.68) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL220648 | 0.93 | TACR1 (0.68) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL7372270 | 0.93 | TACR1 (0.68) | ALDH1A1ALOX15CTSLCTSBCTSS | |
| SCHEMBL26661077 | 0.93 | TACR1 (0.68) | ALDH1A1ALOX15CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180271886-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-9925202-B2 | Treatment of lymphangioleiomyomatosis | BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160129030-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| CN-104628771-B | Antiviral medicine and its medicinal composition | HESI (XI'AN) BIOTECHNOLOGY CO.,LTD. (CN) | 2016-05-11 | — | — | CN | disclosed |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| WO-2014201111-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-12-18 | — | — | WO | disclosed |
| WO-2014137978-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-RE43802-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-11-13 | — | — | US | disclosed |
| US-RE43596-E1 | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2012-08-21 | — | — | US | disclosed |
| US-RE42889-E1 | α- and β- amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors | G.D. SEARLE LLC (US) | 2011-11-01 | — | — | US | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558603-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008688-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| US-4670541-A | Use of diamino alcohols as analgesic agents | E. R. SQUIBB & SONS, INC. (US) | 1987-06-02 | — | — | US | disclosed |
| US-4552866-A | Use of diamino alcohols as analgesic agents | E. R. SQUIBB & SONS, INC. (US) | 1985-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129030-A1 | TREATMENT OF MTOR HYPERACTIVE RELATED DISEASES AND DISORDERS | MTOR, RICTOR, LAMTOR3 | ALDH1A1 4582/4885ALOX15 4355/4885CTSL 105/4885 |
| US-20160022706-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | PTGER1, PTGS1, PTGES | ALDH1A1 3412/4885ALOX15 41/4885CTSL 1566/4885 |
| US-20180271886-A1 | TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS | PTGS1, PTGS2, PTGES2 | ALDH1A1 1618/4885ALOX15 57/4885CTSL 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.